JP2017502003A5 - - Google Patents

Download PDF

Info

Publication number
JP2017502003A5
JP2017502003A5 JP2016538037A JP2016538037A JP2017502003A5 JP 2017502003 A5 JP2017502003 A5 JP 2017502003A5 JP 2016538037 A JP2016538037 A JP 2016538037A JP 2016538037 A JP2016538037 A JP 2016538037A JP 2017502003 A5 JP2017502003 A5 JP 2017502003A5
Authority
JP
Japan
Prior art keywords
phe
pro
tyr
aib
nal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016538037A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502003A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/077240 external-priority patent/WO2015086686A2/en
Publication of JP2017502003A publication Critical patent/JP2017502003A/ja
Publication of JP2017502003A5 publication Critical patent/JP2017502003A5/ja
Pending legal-status Critical Current

Links

JP2016538037A 2013-12-13 2014-12-10 プロテアーゼ耐性ペプチド Pending JP2017502003A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361915662P 2013-12-13 2013-12-13
US61/915,662 2013-12-13
PCT/EP2014/077240 WO2015086686A2 (en) 2013-12-13 2014-12-10 Protease resistant peptides

Publications (2)

Publication Number Publication Date
JP2017502003A JP2017502003A (ja) 2017-01-19
JP2017502003A5 true JP2017502003A5 (enExample) 2017-12-28

Family

ID=52021207

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016538037A Pending JP2017502003A (ja) 2013-12-13 2014-12-10 プロテアーゼ耐性ペプチド

Country Status (11)

Country Link
US (1) US20160318987A1 (enExample)
EP (2) EP3415526A1 (enExample)
JP (1) JP2017502003A (enExample)
KR (1) KR20160098406A (enExample)
CN (1) CN105849123A (enExample)
AU (1) AU2014363547A1 (enExample)
BR (1) BR112016013157A2 (enExample)
CA (1) CA2933405A1 (enExample)
MX (1) MX2016007407A (enExample)
SG (1) SG10201805039UA (enExample)
WO (1) WO2015086686A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI726889B (zh) 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
EP4442314A2 (en) * 2015-10-28 2024-10-09 Tufts University Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
AU2017277594A1 (en) 2016-06-09 2019-02-07 Medimmune Limited Protease-resistant mono-lipidated peptides
US10278957B2 (en) 2017-09-11 2019-05-07 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
UA128210C2 (uk) 2018-04-05 2024-05-08 Сан Фармасьютікал Індастріз Лімітед Аналог glp-1
JP7736315B2 (ja) * 2020-03-31 2025-09-09 アンタロス メディカル アクティエボラーグ イメージング及び治療目的のキレート部分を含む選択的gip受容体アゴニスト
US20240067693A1 (en) * 2020-12-16 2024-02-29 Medimmune Limited Polypeptides and uses thereof
TW202346323A (zh) * 2022-02-07 2023-12-01 英商梅迪繆思有限公司 具有改善的生物穩定性的glp—1及升糖素雙重激動肽
CN121248731A (zh) * 2025-09-18 2026-01-02 内蒙古博睿精创科技有限公司 一种长效降糖减重的多靶点多肽化合物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034331A2 (en) * 1998-12-07 2000-06-15 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Analogues of glp-1
DK1987052T3 (da) * 2006-02-08 2011-08-15 Lonza Ag Syntese af glucagonlignende peptider
WO2007139589A1 (en) * 2006-05-26 2007-12-06 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
EP2057189B1 (en) * 2006-08-25 2013-03-06 Novo Nordisk A/S Acylated exendin-4 compounds
KR101277560B1 (ko) * 2007-12-11 2013-06-25 카딜라 핼쓰캐어 리미티드 글루카곤 안타고니스트 활성 및 glp-1 아고니스트 활성의 펩티드 유사체
EP2110380B1 (en) * 2008-04-18 2010-11-10 F. Hoffmann-La Roche AG Alpha-N-methylation of amino acids
US20120264685A1 (en) * 2009-10-22 2012-10-18 Rajesh Bahekar Short chain peptidomimetics based orally active glp 1 agonist and glucagon receptor antagonist
US20130143800A1 (en) * 2011-11-07 2013-06-06 Research Development Foundation Combination therapies to treat diabetes
AR092873A1 (es) * 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
EP3459598A1 (en) * 2012-12-06 2019-03-27 Stealth Peptides International, Inc. Combinations of peptide therapeutics and methods for using same

Similar Documents

Publication Publication Date Title
AR096162A1 (es) Péptidos terapéuticos
TWI455721B (zh) 癌疫苗組合物
NZ600732A (en) Oxyntomodulin peptide analogue
JP2008510453A5 (enExample)
RU2021134101A (ru) Модифицированная j-цепь
WO2015061416A3 (en) Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
MX2019001925A (es) Proteina de fusion del factor viii de la coagulacion sanguinea humana altamente glicosilada y metodo de fabricacion y aplicacion del mismo.
PH12013500050A1 (en) Anticancer fusion protein
AR086998A1 (es) Coagonistas del receptor de glucagon/glp-1
TW201613958A (en) MIC-1 fusion proteins and uses thereof
NZ624533A (en) Novel immunotherapy against several tumors including neuronal and brain tumors
WO2015188132A8 (en) Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
PE20240015A1 (es) Proteinas de fusion gdf15 y usos de estas
JP2013515055A5 (enExample)
JP2017535527A5 (enExample)
JP2011511753A5 (enExample)
EP4599845A3 (en) Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
CN106232616A (zh) 两亲性合成抗菌肽、其药物组合物及其用途
JP2015516983A5 (enExample)
CO2019013768A2 (es) Compuestos de mic-1 y usos de estos
JP2019525753A5 (enExample)
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
AR096927A1 (es) INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
MX352796B (es) Proteina de fusion anticancerigena.
SA521421371B1 (ar) لقاحات الببتيد